Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBT Margin (2016 - 2025)

Vanda Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 66.42% for Q4 2025.

  • For Q4 2025, EBT Margin fell 5420.0% year-over-year to 66.42%; the TTM value through Dec 2025 reached 64.16%, down 5263.0%, while the annual FY2025 figure was 64.16%, 5263.0% down from the prior year.
  • EBT Margin for Q4 2025 was 66.42% at Vanda Pharmaceuticals, down from 50.46% in the prior quarter.
  • Across five years, EBT Margin topped out at 18.56% in Q2 2021 and bottomed at 74.67% in Q1 2025.
  • The 5-year median for EBT Margin is 1.99% (2023), against an average of 10.69%.
  • The largest annual shift saw EBT Margin skyrocketed 2141bps in 2023 before it tumbled -6485bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 12.66% in 2021, then increased by 18bps to 14.91% in 2022, then plummeted by -125bps to 3.67% in 2023, then tumbled by -233bps to 12.22% in 2024, then crashed by -444bps to 66.42% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBT Margin are 66.42% (Q4 2025), 50.46% (Q3 2025), and 66.34% (Q2 2025).